These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25984279)

  • 1. Serum level of plasminogen activator inhibitor type-1 in addicted patients with coronary artery disease.
    Forood A; Malekpour-Afshar R; Mahdavi A
    Addict Health; 2014; 6(3-4):119-26. PubMed ID: 25984279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease.
    Onalan O; Balta G; Oto A; Kabakci G; Tokgozoglu L; Aytemir K; Altay C; Gurgey A; Nazli N
    J Thromb Thrombolysis; 2008 Dec; 26(3):211-7. PubMed ID: 17721742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
    Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of opium addiction with the severity and extension of myocardial infarction and its related mortality.
    Dehghani F; Masoomi M; Haghdoost AA
    Addict Health; 2013; 5(1-2):35-42. PubMed ID: 24494156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction.
    Soeki T; Tamura Y; Fukuda N; Ito S
    Jpn Circ J; 2000 Aug; 64(8):547-53. PubMed ID: 10952148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
    Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR
    Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activator inhibitor type 1 (PAI-1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in young Asian Indians with acute myocardial infarction.
    Pegoraro RJ; Ranjith N
    Cardiovasc J S Afr; 2005; 16(5):266-70. PubMed ID: 16307159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease.
    Oseroff A; Krishnamurti C; Hassett A; Tang D; Alving B
    J Lab Clin Med; 1989 Jan; 113(1):88-93. PubMed ID: 2783330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
    Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
    Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinolytic variables in postmenopausal women with unstable coronary artery disease.
    Nielsen NE; Logander E; Swahn E
    J Thromb Thrombolysis; 2001 Dec; 12(3):217-23. PubMed ID: 11981104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease.
    Rydzewski A; Sakata K; Kobayashi A; Yamazaki N; Urano T; Takada Y; Takada A
    Haemostasis; 1990; 20(5):305-12. PubMed ID: 2127039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
    Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
    Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing cardiovascular factors in opium abusers and non-users candidate for coronary artery bypass graft surgery.
    Aghadavoudi O; Eizadi-Mood N; Najarzadegan MR
    Adv Biomed Res; 2015; 4():12. PubMed ID: 25625118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease.
    Gardemann A; Lohre J; Katz N; Tillmanns H; Hehrlein FW; Haberbosch W
    Thromb Haemost; 1999 Sep; 82(3):1121-6. PubMed ID: 10494775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
    Hennan JK; Elokdah H; Leal M; Ji A; Friedrichs GS; Morgan GA; Swillo RE; Antrilli TM; Hreha A; Crandall DL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):710-6. PubMed ID: 15860572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.
    Anderson JL; Muhlestein JB; Habashi J; Carlquist JF; Bair TL; Elmer SP; Davis BP
    J Am Coll Cardiol; 1999 Nov; 34(6):1778-83. PubMed ID: 10577569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High PAI activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of myocardial infarction.
    Ihnken K; Speiser W; Ruf W; Thiel W; Schlepper M; Müller-Berghaus G
    Ann Hematol; 1993 Nov; 67(5):237-44. PubMed ID: 8241347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients.
    Peng Y; Liu H; Liu F; Ouyang L; Cheng M; Gao L; Pan F; Liu Y; Chen X; Li J
    Nephrology (Carlton); 2008 Oct; 13(7):579-86. PubMed ID: 19161364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations].
    Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2007; 58(3):213-9. PubMed ID: 17940987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efffect of plasminogen activator inhibitor-1 and endothelin-1 on the atherosclerosis in the maintenance hemodialysis patients].
    Ouyang L; Peng Y; Wu G; Xu X; He Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 May; 38(5):458-67. PubMed ID: 23719522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.